- •The clinical benefit of DOACs in patients with cancer and venous thromboembolism (CAT) is debated.
- •We compared the use of DOACs, VKAs or LMWHs in 4720 patients with CAT.
- •Risk of recurrent VTE was 50% lower in patients who received DOACs compared VKAs.
- •Risk of recurrent VTE was 30% lower in patients who received LMWHs compared to VKAs.
- •Overall rates of major bleedings were similar among the 3 treatment groups.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Venous thromboembolism and cancer: a two-way clinical association.Thromb. Haemost. 1997; 78: 117-120
- Epidemiology and pathophysiology of cancer-associated thrombosis.Br. J. Cancer. 2010; 102: S2-S9
- Long-term anticoagulant therapy of patients with venous thromboembolism. What are the practices?.PLoS One. 2015; 10e0128741https://doi.org/10.1371/journal.pone.0128741
- Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.Blood. 2002; 100: 3484-3488
- Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study.Blood. 2014; 123: 3972-3978
- International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer.Lancet Oncol. 2016; 17: e452-e466
- Antithrombotic therapy for VTE disease. CHEST guidelines and expert panel report.Chest. 2016; 149: 315-352
- Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.N. Engl. J. Med. 2003; 349: 146-153
- Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.Arch. Intern. Med. 2002; 162: 1729-1735
- LITE trial investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer.Am. J. Med. 2006; 119: 1062-1072
- Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period.Clin. Appl. Thromb. Hemost. 2006; 12: 389-396
- Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis.Chest. 2015; 147: 475-483
- Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer.Thromb. Haemost. 2015; 114: 150-157
- Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.Lancet Haematol. 2014; 1: e37-e46
- Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.J. Thromb. Haemost. 2015; 13: 2187-2191
- Hokusai-VTE investigators. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.Lancet Haematol. 2016; 3: e379-e387
- Hokusai VTE cancer investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism.N. Engl. J. Med. 2018; 378: 615-624
- Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic).CMAJ. 2004; 171: 1369-1373
- The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.Ann. Intern. Med. 2015; 162: 777-784
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.BMJ. 2011; d5928: 343
- Demystifying trial networks and network meta-analysis.BMJ. 2013; 346: f2914
- Combination of direct and indirect evidence in mixed treatment comparisons.Stat. Med. 2004; 23: 3105-3124
- Conceptual and technical challenges in network meta-analysis.Ann. Intern. Med. 2013; 159: 130-137
- Effects of hazelnut consumption on blood lipids and body weight: a systematic review and Bayesian meta-analysis.Nutrients. 2016; 8E747
- Generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials.Med. Decis. Mak. 2013; 33: 607-617
- Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales.Stat. Med. 2002; 21: 1601-1623
- Measuring inconsistency in meta-analyses.BMJ. 2003; 327: 557-560
- Checking consistency in mixed treatment comparison meta-analysis.Stat. Med. 2010; 29: 932-944
- Bayesian measures of model complexity and fit.J. R. Stat. Soc. Ser. B Stat Methodol. 2002; 64: 583-639
- The BUGS book.in: A Practical Introduction to Bayesian Analysis. Series Tiss. CRC Press, 2013
- JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling.in: Proceedings of the 3rd International Workshop on Distributed Statistical Computing; Vienna, Austria. March 2003: 20-22
R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; Vienna, Austria: (accessed on 3 September 2013. Available online): http://www.R-project.org/.
- A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis.Eur. J. Vasc. Endovasc. Surg. 2009; 37: 349-356
- CATCH investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial.JAMA. 2015; 314: 677-686
- Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D).J. Clin. Oncol. 2018; (Epub ahead of print)https://doi.org/10.1200/JCO.2018.78.8034
- Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants.Thromb. Res. 2015; 136: 582-589
- Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis.Thromb. Res. 2014; 134: 1214-1219
☆Authors declare that there are no conflict of interest for this manuscript.
☆No financial support was received for this study.